OTLK Stock Forecast & Price Target

Outlook Therapeutics is a biopharmaceutical company focused on developing and commercializing ONS-5010, a potential first-line therapy for wet age-related macular degeneration (AMD). Despite receiving a 3rd Complete Response Letter (CRL) from the FDA in December, the company successfully won their appeal in May and resubmitted their BLA in June, with a decision expected within 60 days. If approved, LYTENAVA could have significant pricing and reimbursement advantages, and the company has various strategies in place to make it the preferred choice over off-label Avastin. Risks to the share price target include failure to demonstrate safety and efficacy in clinical trials and competition, but the potential for significant upside remains.

Outlook Therapeutics is facing significant hurdles to gaining FDA approval for their drug ONS-5010. The company's resubmission of their application in November 2025 was met with a Complete Response Letter due to a lack of substantial evidence of effectiveness, and their first submission in February 2025 was also met with a CRL due to several CMC issues and a lack of substantial evidence. Additionally, the company saw a decline in their European sales and is facing competition from compounded bevacizumab, which could make their drug obsolete. Management's recent partnership with Mediconsult AG does not provide enough visibility into the potential success of the drug, leading to a downgrade from the analyst's previous "BUY" rating.